Sale
Life-Space Urogen Probiotics for Women, Probiotics+Cranberry, 2 Month Serving, Women's Probiotic for PH Balance, Urinary Tract, Digestive & Immune He
AED279.00
AED210.00
About the product
- Formulated with probiotics for women and cranberry extract, our blend offers gentle care for your urinary tract. It helps support your immune system via gut health, maintains a balanced vaginal pH, and works to ease discomfort while helping to prevent occasional issuesgiving you daily peace of mind
- DOCTOR DEVELOPED, IMPROVED COMFORT IN 5 DAYS - Formulated with the #1 clinically studied probiotics for women's urogenital healthGR-1 and RC-14 strainsdeveloped by Dr. Gregor Reid and Dr. Andrew Bruce. In a 30-day human trial, participants reported significant relief by day 30, with improved comfort in just 5 days
- 11 BILLION CFU LIVE STRAINS READY TO WORK - Backed by over 300 clinical trials, our probiotic features double-armor protectionacid-proof and bile-resistantensuring 99.99% of live strains reach your gut alive. Made using pharmaceutical-grade freeze-drying technology for maximum potency. Designed for oral use only; not for vaginal application
- AUSTRALIA'S #1 PROBIOTIC SPECIALIST, GLOBALLY TRUSTED BY FAMILIES - Formulated by AUSTRALIAS LEADING PROBIOTIC SPECIALIST. Our products are proudly made in Australia - A U.S. FDA and Australia's TGA Registered Facility. Trusted for over 20 years across 9 countries, we create scientifically formulated probiotics featuring specific strains, based on rigorous clinical research. Trusted science, premium quality, and real results for a digestive wellness solution you can rely on
- CLINICALLY STUDIED PROBIOTIC STRAINS - Life-Space probiotics feature premium, scientifically validated strains identified by alpha-numeric codes (e.g., Lactobacillus rhamnosus HN001). These codes indicate strains with documented clinical research supporting their safety and efficacy. Probiotic products lacking strain-specific identification (e.g., unnamed "Lactobacillus rhamnosus") have not been clinically evaluated for targeted benefits